Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers.
Authors
Dowling, Gavin PDaly, Gordon R
Hegarty, Aisling
Flanagan, Michael
Ola, Mihaela
Fallon, Ramón
Cocchiglia, Sinéad
Singh, Vikrant
Sheehan, Katherine M
Bane, Fiona
McGrath, Jason
Watson, Louise
Hembrecht, Sandra
Hennessy, Bryan
Morris, Patrick G
Hill, Arnold D K
Varešlija, Damir
Young, Leonie S
Issue Date
2024-12-15Keywords
HER2ESR1
breast cancer
DNA
Metadata
Show full item recordCitation
Dowling, G. P., Daly, G. R., Hegarty, A., Flanagan, M., Ola, M., Fallon, R., Cocchiglia, S., Singh, V., Sheehan, K. M., Bane, F., McGrath, J., Watson, L., Hembrecht, S., Hennessy, B., Morris, P. G., Hill, A. D. K., Varešlija, D., & Young, L. S. (2025). Neoadjuvant HER2 inhibition induces ESR1 DNA methylation alterations resulting in clinically relevant ER expression changes in breast cancers. Cancer communications (London, England), 45(2), 198–202. https://doi.org/10.1002/cac2.12640Publisher
WileyJournal
Cancer communications (London, England)DOI
10.1002/cac2.12640PubMed ID
39676516PubMed Central ID
PMC11833670Item Type
ArticleLanguage
enEISSN
2523-3548ae974a485f413a2113503eed53cd6c53
10.1002/cac2.12640
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Related articles
- Transcriptional implications of intragenic DNA methylation in the oestrogen receptor alpha gene in breast cancer cells and tissues.
- Authors: Shenker NS, Flower KJ, Wilhelm-Benartzi CS, Dai W, Bell E, Gore E, El Bahrawy M, Weaver G, Brown R, Flanagan JM
- Issue date: 2015 May 1
- ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients.
- Authors: Martínez-Galán J, Torres-Torres B, Núñez MI, López-Peñalver J, Del Moral R, Ruiz De Almodóvar JM, Menjón S, Concha A, Chamorro C, Ríos S, Delgado JR
- Issue date: 2014 Feb 4
- RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.
- Authors: Denkert C, Loibl S, Kronenwett R, Budczies J, von Törne C, Nekljudova V, Darb-Esfahani S, Solbach C, Sinn BV, Petry C, Müller BM, Hilfrich J, Altmann G, Staebler A, Roth C, Ataseven B, Kirchner T, Dietel M, Untch M, von Minckwitz G
- Issue date: 2013 Mar
- Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
- Authors: Iwata H, Masuda N, Yamamoto Y, Fujisawa T, Toyama T, Kashiwaba M, Ohtani S, Taira N, Sakai T, Hasegawa Y, Nakamura R, Akabane H, Shibahara Y, Sasano H, Yamaguchi T, Sakamaki K, Bailey H, Cherbavaz DB, Jakubowski DM, Sugiyama N, Chao C, Ohashi Y
- Issue date: 2019 Jan
- Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations.
- Authors: Boscolo Bielo L, Guerini Rocco E, Trapani D, Zagami P, Taurelli Salimbeni B, Esposito A, Belli C, Crimini E, Venetis K, Munzone E, Fusco N, Criscitiello C, Marra A, Curigliano G
- Issue date: 2024 Oct